Deals
The Man Behind India's Best Stock Faces His Biggest Test
- Sun Pharma faces challenges after two-decade run of growth
- Shares have hit a wall after surging over past 20 years
Dilip Shanghvi.
Photographer: Kuni Takahashi/BloombergThis article is for subscribers only.
When Dilip Shanghvi wants something, he has a track record of getting it.
One executive, Srinivas Lanka, recalls the founder of Sun Pharmaceuticals Industries Ltd. calling more than 100 times over three years with a job offer two decades ago. Shanghvi was setting off on an acquisition-fueled strategy to transform his small generic drugmaker into an industry powerhouse, and he wouldn’t take no for an answer.